DGX 8-K Current Reports
QUEST DIAGNOSTICS INC - 304 current reports
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jul 23, 2026)
Quest Diagnostics Incorporated (DGX) has filed an 8-K report on July 23, 2026, to announce its financial results for the quarter ended June 30, 2026. The primary focus of this filing is the dissemination of these quarterly results, as detailed in the attached press release (Exhibit 99.1). Investors should refer to this press release for specific financial performance metrics, including revenue, earnings, and any forward-looking guidance provided by the company for the upcoming periods. While the 8-K itself is brief, indicating the press release contains the substance of the announcement, it serves as a formal notification to the market. The filing primarily confirms the release of Q2 2026 earnings and provides the official record for their disclosure. Investors are encouraged to review the accompanying press release for comprehensive details on the company's operational and financial condition, management's commentary, and any strategic updates.
QUEST DIAGNOSTICS INC 8-K Report, Shareholder Vote Results (May 21, 2026)
Quest Diagnostics Inc. (DGX) filed an 8-K report on May 21, 2026, detailing the results of its 2026 Annual Meeting of Stockholders held on May 20, 2026. The primary focus of this filing is the voting outcomes on key corporate governance matters, including director elections and executive compensation. The company saw overwhelming support for its nominated directors, with all nominees being re-elected with substantial 'For' votes, indicating strong shareholder confidence in the current board leadership. Furthermore, shareholders approved the executive compensation as disclosed in the 2026 Proxy Statement through an advisory resolution, and also ratified the appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year 2026. Notably, a stockholder proposal advocating for an independent board chairman was not approved, reflecting a preference for the current board structure. Overall, the results signal a positive shareholder sentiment regarding the company's governance and financial oversight.
QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (May 8, 2026)
Quest Diagnostics Incorporated (DGX) has announced the issuance of $500 million in aggregate principal amount of 5.000% senior notes due 2036. This offering, detailed under Item 1.01 of their Form 8-K filed on May 8, 2026, represents a significant debt financing event for the company. The notes will mature on June 30, 2036, and will bear interest payable semi-annually. These senior unsecured notes rank equally with existing and future senior unsecured obligations of Quest Diagnostics. The issuance is governed by an indenture, which includes covenants restricting the company and certain subsidiaries from creating specific liens and entering into certain sale and leaseback transactions. Additionally, limitations are placed on the company's ability to consolidate, merge, or transfer substantially all of its assets. In the event of a change of control triggering event, Quest Diagnostics will be obligated to offer to repurchase the notes at 101% of their principal amount plus accrued interest.
QUEST DIAGNOSTICS INC 8-K Report, Corporate Update (May 1, 2026)
Quest Diagnostics Incorporated (DGX) has announced the pricing of a $500 million public offering of 5.000% senior notes due 2036. This offering, conducted under the company's shelf registration statement, is set to close on May 6, 2026, with net proceeds intended for general corporate purposes. A significant portion of these proceeds may be used to repay existing indebtedness, specifically the $500 million aggregate principal amount of 3.45% Senior Notes maturing on June 1, 2026. This proactive debt management strategy aims to refinance maturing debt with new, longer-term notes. Investors should note the timing of the offering's closing just ahead of the maturity date of the existing notes. The company has also entered into an underwriting agreement with major financial institutions, including Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Mizuho Securities USA LLC, for this transaction.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Apr 21, 2026)
Quest Diagnostics Incorporated (DGX) filed an 8-K on April 21, 2026, to report its financial results for the quarter ended March 31, 2026. The primary purpose of this filing is to provide investors with the company's performance during the first quarter of 2026, as detailed in an attached press release. While the filing itself is procedural, referencing the press release (Exhibit 99.1) is crucial for understanding key financial metrics, revenue performance, profitability, and any forward-looking statements or guidance provided by the company. Investors should review the press release to assess the company's operational execution and its implications for future financial health and stock valuation.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Mar 12, 2026)
Quest Diagnostics Incorporated (DGX) has announced a significant addition to its Board of Directors through the election of Timothy Wentworth, formerly the chief executive officer of Walgreens Boots Alliance. This appointment, effective March 9, 2026, brings a seasoned executive with extensive experience in the healthcare and retail pharmacy sectors to the company's leadership. Mr. Wentworth has been appointed to serve on the Board's Compensation and Leadership Development Committee and the Quality and Compliance Committee, signaling a focus on critical governance areas. His designation as an independent director, confirmed by both New York Stock Exchange standards and the Company's own guidelines, suggests alignment with best practices in corporate governance. Investors may view this as a positive step towards enhancing board expertise and oversight.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Feb 10, 2026)
Quest Diagnostics Incorporated (DGX) has filed an 8-K report on February 10, 2026, detailing its financial results for the fiscal year and fourth quarter ended December 31, 2025, and announcing significant capital return initiatives. While specific financial figures from the press release are not detailed in this extract, the filing indicates that the company is sharing its operational and financial performance with investors. This update is crucial for understanding the company's recent performance and outlook. The accompanying press releases, incorporated by reference, contain the detailed financial outcomes that investors should review for a comprehensive understanding. Beyond the financial results, Quest Diagnostics is demonstrating a strong commitment to shareholder returns. The Board of Directors has authorized an additional $1 billion for common stock repurchases, signaling confidence in the company's valuation and financial health. Furthermore, the quarterly dividend has been increased by 7.5% from $0.80 to $0.86 per share, effective for the dividend payable in April 2026. This enhanced return to shareholders, combined with the share repurchase program, suggests a positive financial trajectory and a focus on enhancing shareholder value.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jan 12, 2026)
Quest Diagnostics Incorporated (DGX) filed an 8-K on January 12, 2026, to disclose their participation in the 44th Annual J.P. Morgan Healthcare Conference. The primary purpose of this filing is to furnish the presentation materials that management will use during their discussion of the Company's strategy, performance, and current market trends. While this filing does not contain new financial results or operational updates, investors should note that the accompanying presentation materials (Exhibit 99.1) are incorporated by reference. These materials may contain forward-looking statements regarding management's current outlook, projections, and expectations. Investors are cautioned to review these statements alongside the risks and uncertainties detailed in Quest Diagnostics' other SEC filings, including their most recent 10-K and 10-Q reports, as actual results could materially differ.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Oct 21, 2025)
Quest Diagnostics Incorporated (DGX) has filed an 8-K report on October 21, 2025, disclosing its financial results for the quarter ended September 30, 2025. The press release, incorporated by reference, provides key operational and financial performance metrics. Investors should pay close attention to the details within this press release for a comprehensive understanding of the company's recent performance and its implications for future financial health and strategic direction. While the 8-K itself is brief and primarily serves to attach the press release, the substance of the filing lies within the attached document. This includes crucial information regarding revenue, profitability, earnings per share, and any significant business developments or outlooks provided by management. Investors are encouraged to review Exhibit 99.1 for a detailed breakdown of the quarterly performance and any forward-looking statements.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jul 22, 2025)
Quest Diagnostics Incorporated (DGX) has filed an 8-K report on July 22, 2025, to disclose its financial results for the quarter ended June 30, 2025. The primary driver of this filing is the accompanying press release (Exhibit 99.1), which details the company's performance and financial condition. Investors should closely examine this press release for specific figures related to revenue, profitability, and any forward-looking statements or guidance provided by the company for the upcoming periods. While the 8-K itself is procedural, the substance lies within the attached press release. Key metrics such as earnings per share (EPS), revenue growth, and operating margins will be crucial for assessing Quest Diagnostics' operational success and its position within the competitive laboratory testing market. Any significant deviations from prior periods or analyst expectations, whether positive or negative, will likely impact the stock's valuation and investor sentiment.
QUEST DIAGNOSTICS INC 8-K Report, Shareholder Vote Results (May 22, 2025)
Quest Diagnostics Inc. (DGX) filed an 8-K on May 22, 2025, reporting the voting results from its 2025 Annual Meeting of Stockholders held on May 15, 2025. The filing confirms the election of all nominated directors to serve until the 2026 Annual Meeting, with overwhelming support from shareholders. Additionally, the advisory resolution on executive compensation was approved, reflecting shareholder confidence in the company's pay practices. The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for 2025 also received strong ratification from stockholders. Notably, a stockholder proposal seeking the ability to call a special meeting did not pass, indicating that current governance structures remain favored by the majority. Overall, the results suggest a stable shareholder base supportive of current management and board leadership.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Apr 22, 2025)
Quest Diagnostics Incorporated (DGX) has filed an 8-K report on April 22, 2025, to announce its financial and operational results for the quarter ended March 31, 2025. The primary driver of this filing is the accompanying press release (Exhibit 99.1), which details the company's performance during the period. Investors should review this press release for specific financial metrics, including revenue, profitability, and any forward-looking guidance or commentary provided by management. While the 8-K itself is a procedural document incorporating the press release, the press release contains the substance of the company's quarterly update. Key information investors will likely seek includes year-over-year and sequential performance trends, an understanding of the drivers behind these trends (e.g., volume, pricing, service mix), and any strategic initiatives or challenges that may impact future results. This filing serves as the official channel for disseminating these critical quarterly updates.
QUEST DIAGNOSTICS INC 8-K Report, Regulation FD Disclosure (Mar 19, 2025)
Quest Diagnostics Incorporated (DGX) filed an 8-K on March 19, 2025, to disclose information presented at its Investor Day. During this event, the company's leadership team outlined strategies aimed at fostering sustainable growth and enhancing long-term shareholder value. The detailed presentation materials, furnished as exhibits to this filing, provide insights into the company's strategic vision and future outlook. While this filing does not contain new financial results or material business changes, it serves as a communication channel for management's perspectives on the company's direction. Investors are encouraged to review the provided presentation materials for a deeper understanding of Quest Diagnostics' plans, particularly concerning its growth initiatives and how it intends to deliver value to its shareholders. The company also included standard cautionary language regarding forward-looking statements and the inherent risks and uncertainties associated with its business.
QUEST DIAGNOSTICS INC 8-K Report, Regulation FD Disclosure (Mar 19, 2025)
Quest Diagnostics Incorporated (DGX) filed an 8-K on March 19, 2025, to announce its Investor Day event. During this event, the company's leadership team is set to discuss strategies aimed at fostering sustainable growth and enhancing long-term shareholder value. A key component of this announcement is the issuance of a press release that reiterates previously provided guidance for the full-year 2025 and outlines the company's outlook beyond 2025. Investors should note that the press release and presentation materials, furnished as exhibits, contain forward-looking statements. While these provide insight into management's current expectations and long-term vision, they are subject to risks and uncertainties that could materially impact actual results. The company has referenced its SEC filings, including its most recent 10-K, for a comprehensive discussion of these potential risks.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jan 30, 2025)
Quest Diagnostics Incorporated (DGX) filed an 8-K on January 30, 2025, to report its financial and operational updates. The filing primarily references a press release containing the company's results for the fourth quarter and full year ended December 31, 2024. While specific financial figures from the press release are not detailed within the 8-K itself, this release is a key source of information for investors assessing the company's recent performance. The 8-K also highlights a significant capital return initiative, signaling confidence in the company's financial health and commitment to shareholder value.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Oct 22, 2024)
Quest Diagnostics Incorporated (DGX) filed an 8-K on October 22, 2024, to report its financial results for the quarter ended September 30, 2024. The primary purpose of this filing is to furnish the accompanying press release, which contains the company's operational and financial performance for the specified period. Investors should refer to the press release (Exhibit 99.1) for detailed financial figures, including revenue, profitability, and any forward-looking statements or guidance provided by management. While the 8-K itself is a brief announcement, the attached press release is where the substantive details lie. Investors are encouraged to review this document to understand Quest Diagnostics' performance in the third quarter of 2024, assess trends, and evaluate the company's current financial health and future outlook. The filing indicates that the company is adhering to its reporting obligations by promptly disseminating this information to the public.
QUEST DIAGNOSTICS INC 8-K Report, Corporate Update (Aug 29, 2024)
Quest Diagnostics Incorporated (DGX) announced the closing of its acquisition of LifeLabs Inc. on August 26, 2024. This strategic move, previously disclosed on July 3, 2024, involves acquiring a Canadian company that offers laboratory diagnostic information and digital health connectivity systems. The acquisition is expected to expand Quest Diagnostics' geographic footprint and service offerings within the Canadian market, potentially enhancing its competitive position and revenue streams in the long term. Investors should note that this filing primarily serves to confirm the closing of the transaction. Further details regarding the financial implications and integration of LifeLabs into Quest Diagnostics' operations will likely be provided in future filings or investor communications. The company has filed the press release regarding this announcement as an exhibit to this report, which may offer additional context.
QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Aug 19, 2024)
Quest Diagnostics Incorporated (DGX) has filed an 8-K report detailing the issuance of a substantial amount of senior unsecured notes across three tranches, totaling $1.85 billion. These notes include $400 million due 2027 at 4.600%, $600 million due 2029 at 4.625%, and $850 million due 2034 at 5.000%. The proceeds from this offering are likely intended to fund ongoing strategic initiatives, including a previously disclosed acquisition. This significant debt issuance warrants investor attention regarding the company's leverage profile and capital structure. The filing also notes that the 2027 and 2029 notes will be subject to redemption at 101% of their principal amount if the previously announced acquisition of LifeLabs, Inc. is not consummated by a specified deadline or if Quest Diagnostics decides not to proceed with the acquisition. The 2034 notes, however, will remain outstanding regardless of the acquisition's outcome. Additionally, the company has amended its By-Laws to provide exculpation for officers, aligning with prior stockholder approvals.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jul 23, 2024)
Quest Diagnostics Incorporated (DGX) filed an 8-K on July 23, 2024, to announce its financial results for the quarter ended June 30, 2024. The core of this filing is the attached press release (Exhibit 99.1), which provides the company's performance update for the period. Investors should refer to this press release for detailed financial figures, operational performance, and any forward-looking statements or guidance provided by the company. While the 8-K itself is a formal notification of the earnings release, the actual substance of the financial results, including revenue, profitability, and key performance indicators, will be found within the incorporated press release. Investors are encouraged to review Exhibit 99.1 for a comprehensive understanding of Quest Diagnostics' recent financial condition and operational outcomes.
QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Jul 3, 2024)
Quest Diagnostics Incorporated (DGX) has announced a significant strategic move through an Equity Purchase Agreement to acquire LifeLabs Inc. and BPC LP. This transaction, valued at approximately CAD 1.35 billion (USD 985 million) including net debt, involves purchasing all shares and partnership interests of the Canadian diagnostic information and digital health connectivity providers. The acquisition is expected to be completed by the end of 2024, subject to customary closing conditions, including regulatory approvals under the Competition Act (Canada) and the Investment Canada Act, as well as consents from key customers. This move represents a material expansion for Quest Diagnostics into the Canadian market, aiming to enhance its service offerings and market presence. Investors should monitor the satisfaction of the closing conditions, as failure to obtain necessary approvals could result in a termination fee for Quest Diagnostics. The company has also entered into restrictive covenants regarding the operations of the Target Entities during the interim period, underscoring the definitive nature of the agreement.
QUEST DIAGNOSTICS INC 8-K Report, Bylaw Amendment (May 21, 2024)
Quest Diagnostics Inc. (DGX) filed an 8-K on May 21, 2024, reporting on outcomes from its Annual Meeting of Stockholders held on May 16, 2024. Key among these outcomes is the approval by stockholders of an amendment to the Company's Restated Certificate of Incorporation. This amendment allows for the exculpation of officers, a measure permitted by Delaware law, designed to shield officers from personal liability for certain breaches of fiduciary duty. This change was officially filed with the Secretary of State of Delaware on May 20, 2024. Additionally, the filing details the voting results for director elections, executive compensation approval, and the ratification of PricewaterhouseCoopers as the independent auditor. While director elections and auditor ratification passed with strong support, the advisory vote on executive compensation was also approved. Notably, a stockholder proposal concerning climate risk management was not approved, indicating differing views on the urgency or approach to setting science-based targets and transition planning.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (May 21, 2024)
Quest Diagnostics Incorporated (DGX) announced the appointment of Robert B. Carter to its Board of Directors, effective May 16, 2024. Mr. Carter brings significant executive experience, currently serving as Executive Vice President and Chief Information Officer at FedEx Corporation, and Co-President and Co-CEO of FedEx Services. His addition to the Board is expected to enhance the company's strategic oversight and digital transformation efforts, given his extensive background in technology and corporate leadership. The Board has determined that Mr. Carter meets the independence criteria set forth by the New York Stock Exchange and the Company's own governance guidelines. His appointment as a non-employee director means he will be compensated according to the company's standard practices for its non-employee directors. Further details regarding committee assignments are pending.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Apr 23, 2024)
Quest Diagnostics Incorporated (DGX) filed an 8-K on April 23, 2024, to report its financial results for the quarter ended March 31, 2024. The primary purpose of this filing is to provide investors with early access to the company's performance data as announced in their press release, which is incorporated by reference. Investors should review the press release (Exhibit 99.1) for detailed financial metrics, operational performance, and any forward-looking statements or guidance provided by the company. While the 8-K itself does not contain the detailed financial statements, it serves as a formal notification of the release of this information. Key details regarding revenue, earnings per share, segment performance, and any management commentary on business trends or strategic initiatives would be found within the accompanying press release. Investors interested in the company's immediate financial standing and outlook should consult this exhibit.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Feb 1, 2024)
Quest Diagnostics Incorporated (DGX) filed an 8-K on February 1, 2024, primarily detailing its fourth quarter and full-year 2023 financial results and a significant capital return to shareholders. While the full financial details are in the referenced press release, the key takeaway for investors is the board's authorization of a 5.6% increase in the quarterly dividend, raising it to $0.75 per share ($3.00 annually). This marks the 13th consecutive year of dividend increases, underscoring the company's commitment to shareholder returns and financial stability. Investors should also note the announcement of the Q4 and FY 2023 results, which are incorporated by reference. While specific figures are not detailed within the 8-K text provided, this filing serves as the official notification of these results. The dividend increase, in particular, signals management's confidence in the company's ongoing performance and ability to generate sufficient cash flow to reward its shareholders.
QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Nov 1, 2023)
Quest Diagnostics Incorporated (DGX) has filed a Form 8-K to report on the issuance of $750 million aggregate principal amount of 6.400% senior notes due 2033. This debt offering, priced on October 30, 2023, and issued on November 1, 2023, aims to raise capital for the company. The notes are senior unsecured obligations and will rank equally with existing and future senior unsecured debt. The issuance was conducted under the company's shelf registration statement and involved an underwriting agreement with several prominent financial institutions. This filing indicates a strategic move by Quest Diagnostics to secure long-term financing. Investors should note the coupon rate of 6.400% and the maturity date of November 30, 2033. The indenture includes covenants that may restrict certain actions by the company and its subsidiaries, such as creating liens or engaging in sale and leaseback transactions, and also contains provisions for a mandatory repurchase offer at 101% of principal in the event of a change of control triggering event.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Oct 24, 2023)
Quest Diagnostics Incorporated (DGX) filed an 8-K on October 24, 2023, to announce its financial results for the quarter ended September 30, 2023. The filing primarily consists of a press release detailing these results. Investors should refer to the attached press release (Exhibit 99.1) for specific financial and operational performance metrics. This 8-K serves as the official notification of the company's performance during the third quarter of 2023. While the 8-K itself doesn't contain the detailed analysis, it directs stakeholders to the press release for the core information. Investors interested in understanding Quest Diagnostics' performance, including revenue, profitability, and any forward-looking statements or guidance, will need to examine the content of Exhibit 99.1. This filing is a standard procedure for publicly traded companies to promptly disclose material financial information.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Sep 29, 2023)
This 8-K filing from Quest Diagnostics Incorporated (DGX) reports a change in its Board of Directors. Dr. Gail R. Wilensky has decided not to seek re-election at the upcoming 2024 Annual Stockholders Meeting and will retire from the Board at that time, upon the expiration of her current term. This is a voluntary decision by Dr. Wilensky, not a result of any disagreement with the Company. While the departure of a board member can sometimes signal strategic shifts or governance considerations, the filing indicates this is a planned retirement upon the conclusion of her term. Investors should note this change but recognize it as a standard transition unless further information is provided by the company regarding the reasons for her decision or any replacement appointments. The effective date of her retirement is tied to the 2024 Annual Stockholders Meeting, expected in May 2024.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jul 26, 2023)
Quest Diagnostics Incorporated (DGX) filed an 8-K on July 26, 2023, primarily to report its financial results for the quarter ended June 30, 2023. While the filing itself is brief, it directs investors to an attached press release (Exhibit 99.1) for detailed operational and financial performance information. Investors should review this press release for specific figures related to revenue, earnings, and any forward-looking statements or guidance provided by the company. The core purpose of this filing is to ensure public disclosure of material financial information in a timely manner. Investors relying on this report should understand that the 8-K serves as a notification and incorporation by reference to the more comprehensive earnings announcement. Therefore, the real substance of the company's quarterly performance, management's commentary, and future outlook will be found within the press release itself, which is considered an integral part of this filing.
QUEST DIAGNOSTICS INC 8-K Report, Shareholder Vote Results (May 19, 2023)
This 8-K filing from Quest Diagnostics Inc. (DGX) details the voting results from their Annual Meeting of Stockholders held on May 17, 2023. Key outcomes include the overwhelming re-election of all director nominees, indicating strong shareholder confidence in the current board leadership. The advisory resolution to approve executive compensation was also approved, though with a notable percentage of opposition, suggesting some shareholders may have reservations regarding pay practices. Furthermore, shareholders voted to ratify the appointment of PricewaterhouseCoopers as the independent auditor, ensuring continued oversight of financial reporting.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Apr 27, 2023)
Quest Diagnostics Incorporated (DGX) filed an 8-K on April 27, 2023, announcing both its first-quarter 2023 financial results and a significant strategic acquisition. The company reported its financial performance for the quarter ended March 31, 2023, details of which are available in an attached press release. This announcement provides investors with an update on the company's operational and financial standing at the beginning of the fiscal year. In addition to the financial results, Quest Diagnostics also revealed its definitive agreement to acquire Haystack Oncology, Inc. This move signifies a strategic expansion into the rapidly growing field of minimal residual disease (MRD) testing within oncology. The acquisition is expected to enhance the company's capabilities in precision oncology and represents a key growth initiative for Quest Diagnostics, aiming to capture opportunities in advanced diagnostic services.
QUEST DIAGNOSTICS INC 8-K Report, Regulation FD Disclosure (Mar 17, 2023)
Quest Diagnostics Incorporated (DGX) filed an 8-K on March 17, 2023, primarily to disclose information presented at their Investor Day held on March 16, 2023. During this event, management provided an updated perspective on the U.S. laboratory market, the company's strategic direction, capital allocation priorities, and long-term financial outlook. Key takeaways include the reiteration of previously issued full-year 2023 guidance and an updated outlook spanning the 2023 to 2026 period. Investors should note that the detailed information, including a press release and presentation materials, is furnished as an exhibit to this 8-K. While this filing does not typically involve new financial statements, the provided materials offer insights into management's expectations and strategic plans. Investors are encouraged to review these exhibits for a comprehensive understanding of the company's forward-looking statements and the associated risks and uncertainties, which are further detailed in Quest Diagnostics' other SEC filings.
QUEST DIAGNOSTICS INC 8-K Report, Corporate Update (Mar 7, 2023)
Quest Diagnostics Incorporated (DGX) announced a significant leadership transition through a press release filed on March 7, 2023, related to events on March 3, 2023. The Board of Directors has elected James E. Davis, the current Chief Executive Officer and President, to also assume the role of Chairman of the Board, effective April 1, 2023. This move consolidates leadership under Mr. Davis, who has been CEO and President since October 1, 2021. He will succeed Stephen H. Rusckowski, who has held the Chairman position since January 1, 2017. Investors should view this as a signal of continued strategic direction under Mr. Davis's leadership, potentially indicating a focus on executing current growth initiatives and operational efficiencies without immediate disruption from a new external leadership perspective. The separation of CEO and Chairman roles is a common governance practice, and their consolidation can sometimes streamline decision-making, though it is important to monitor board independence going forward.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Feb 2, 2023)
Quest Diagnostics Inc. (DGX) filed an 8-K on February 2, 2023, detailing key financial and shareholder return actions. The company announced its financial results for the fourth quarter and full year ended December 31, 2022. While specific figures from the earnings release are not detailed in the 8-K itself, this filing serves as the official notification of their release, directing investors to Exhibit 99.1 for comprehensive performance data. Beyond earnings, the report highlights significant capital allocation decisions aimed at enhancing shareholder value. Quest Diagnostics' Board of Directors authorized an additional $1 billion for common stock repurchases, underscoring management's confidence in the company's stock and its commitment to returning capital to shareholders. Furthermore, the quarterly dividend was increased from $0.66 to $0.71 per share, marking the twelfth dividend increase since 2011, indicating a consistent track record of dividend growth.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Nov 18, 2022)
Quest Diagnostics Incorporated (DGX) filed an 8-K on November 18, 2022, primarily detailing changes related to its executive team and corporate governance. The company announced the appointment of four new executive officers: Mark E. Delaney, Mark A. Gardner, Karthik Kuppusamy, and Patrick T. Plewman. These individuals have been elevated to executive officer roles and will participate in the company's Executive Officer Severance Plan, indicating a formalization of their roles and associated benefits. Additionally, Quest Diagnostics amended and restated its By-Laws, effective November 14, 2022. These revisions specifically address director nominations and proxy solicitations, including updates for compliance with Rule 14a-19 under the Securities Exchange Act of 1934. While these changes are largely procedural and clarifying, they signal the company's commitment to adhering to updated regulatory requirements and best practices in corporate governance.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Nov 1, 2022)
Quest Diagnostics Inc. (DGX) announced significant leadership changes effective November 1, 2022. The company's Board of Directors has appointed James E. Davis as the new Chief Executive Officer and President, taking over these roles from Stephen H. Rusckowski, who will continue to serve as Chairman of the Board. This transition marks a key moment for the company's strategic direction and operational leadership. Furthermore, the Board also increased its size from 9 to 10 directors and elected Mr. Davis to fill the newly created vacancy. These changes, detailed in an 8-K filing dated November 1, 2022, are accompanied by a press release (Exhibit 99.1) providing further context on this executive transition. Investors should monitor Mr. Davis's initial strategies and priorities as the new CEO.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Oct 28, 2022)
Quest Diagnostics Incorporated (DGX) filed an 8-K on October 28, 2022, to disclose significant changes to the compensation package for Mr. Davis upon his promotion to Chief Executive Officer and President, effective November 1, 2022. These changes reflect his expanded responsibilities and aim to align his incentives with the company's performance and long-term value creation. The updated compensation includes a substantial increase in base salary, a higher target for annual incentives, and revised severance plan participation. Additionally, Mr. Davis will receive enhanced benefits such as transportation allowances and relocation assistance. A significant equity grant valued at $5,000,000, comprised of performance shares and restricted stock units, underscores the company's commitment to retaining and motivating its new CEO.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Oct 20, 2022)
Quest Diagnostics Incorporated (DGX) filed an 8-K on October 20, 2022, primarily to report its financial results for the quarter ended September 30, 2022. The accompanying press release, incorporated by reference, provides the key financial and operational details for the period. Investors should review this filing to understand the company's performance, including revenue, profitability, and any significant business updates that may impact future outlook. The report itself is brief, indicating that the core information is contained within the press release. Therefore, investors should pay close attention to the details within Exhibit 99.1 for a comprehensive understanding of the company's recent performance and any forward-looking statements or guidance provided by management.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jul 21, 2022)
Quest Diagnostics Incorporated (DGX) filed an 8-K on July 21, 2022, to announce its financial results for the quarter ended June 30, 2022. The primary purpose of this filing is to provide investors with updated operational and financial performance information. Investors should review the attached press release for detailed insights into the company's performance during the second quarter of 2022, which includes key financial metrics and operational highlights. The filing itself is brief, directing readers to the press release (Exhibit 99.1) for the substance of the announcement. This means the critical information regarding revenue, earnings per share, and any forward-looking guidance or significant business developments will be found within that press release. Investors should pay close attention to any commentary on trends in diagnostic testing volumes, pricing, and the company's strategic initiatives.
QUEST DIAGNOSTICS INC 8-K/A Report, Executive Changes (Jul 1, 2022)
This 8-K filing is an amendment to a previous report concerning leadership changes at Quest Diagnostics Inc. (DGX). The primary update is regarding the compensation and transition arrangements for Stephen H. Rusckowski, the current Chairman, CEO, and President. Mr. Rusckowski is set to retire as CEO and President on November 1, 2022, and will transition to the role of Executive Chairman until March 31, 2023. His existing employment agreement will not be renewed as he steps down from his executive roles. However, his compensation for his continued service as Executive Chairman is expected to remain generally aligned with his 2022 compensation. This filing provides clarity on the financial implications of this executive transition for a key leadership figure, which is important for understanding executive compensation policies and leadership continuity.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Jun 14, 2022)
Quest Diagnostics Incorporated (DGX) announced a significant leadership change, appointing Sam Samad as its new Executive Vice President and Chief Financial Officer, effective July 25, 2022. Mr. Samad brings extensive financial experience from his previous roles, most notably as CFO at Illumina, Inc., and various senior positions at Cardinal Health and Eli Lilly and Company. This appointment follows the announced retirement of Mark Guinan, who served as CFO. The company has structured Mr. Samad's compensation package to include a competitive base salary, incentive bonuses, and substantial equity awards, including both performance-based and sign-on grants to offset previous employer forfeitures. Investors should note the comprehensive onboarding package and the standard restrictive covenants and executive benefits that accompany his new role.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (May 25, 2022)
Quest Diagnostics Incorporated (DGX) filed an 8-K on May 25, 2022, to report a significant executive departure. Carrie Eglinton Manner, Senior Vice President of Advanced and General Diagnostics and Clinical Solutions, resigned from her position, with her departure effective June 3, 2022. Ms. Manner is leaving to join OraSure Technologies, Inc. This change in leadership within a key division may impact strategic execution and operational continuity in advanced diagnostics and clinical solutions. Investors should monitor how the company addresses this vacancy and redistributes responsibilities. While the filing itself is brief and primarily focused on this personnel change, the effective date suggests that Ms. Manner will remain with Quest Diagnostics for a short transition period. The news of her departure, particularly to a competitor or related industry company, warrants attention regarding potential impacts on competitive strategies and talent retention. Investors will be looking for updates on the succession plan for her role and any immediate operational changes.
QUEST DIAGNOSTICS INC 8-K Report, Bylaw Amendment (May 20, 2022)
Quest Diagnostics Incorporated (DGX) filed an 8-K on May 20, 2022, to report significant amendments to its corporate governance documents. These changes, approved by stockholders at the May 18, 2022 Annual Meeting and effective May 19, 2022, aim to enhance shareholder rights and engagement. Key among these are the new provisions allowing stockholders to take certain actions by written consent (previously requiring unanimous consent) and lowering the threshold for stockholders to request a special meeting from 20% to 15% ownership, subject to specific requirements. These amendments to the Certificate of Incorporation and corresponding By-Laws were designed to provide shareholders with more flexibility in corporate decision-making and to facilitate greater participation in company governance. Investors should note that these changes are effective immediately and reflect the company's responsiveness to shareholder input on corporate governance matters, potentially leading to a more engaged shareholder base.
QUEST DIAGNOSTICS INC 8-K Report, Shareholder Vote Results (May 20, 2022)
Quest Diagnostics Inc. (DGX) filed an 8-K on May 20, 2022, reporting the results of its 2022 Annual Meeting of Stockholders held on May 18, 2022. The meeting primarily focused on shareholder votes regarding director elections, executive compensation, auditor ratification, and amendments to the company's charter. All director nominees were elected with strong support. Additionally, shareholders approved the advisory resolution on executive compensation and ratified the appointment of PricewaterhouseCoopers as the independent auditor.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Apr 21, 2022)
Quest Diagnostics Incorporated (DGX) filed an 8-K on April 21, 2022, to announce its financial results for the quarter ended March 31, 2022. The filing primarily incorporates by reference a press release detailing these results. While the 8-K itself doesn't provide the specific figures, the attached press release serves as the primary source of information for investors to assess the company's performance during the first quarter of 2022. Investors should review the press release for key financial metrics, operational updates, and forward-looking statements made by the company.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Mar 2, 2022)
This 8-K filing from Quest Diagnostics (DGX) primarily announces the departure of Dr. Helen I. Torley from the Board of Directors. Dr. Torley, who also serves as President and CEO of Halozyme Therapeutics, has decided not to seek re-election at the upcoming Annual Meeting of Stockholders on May 18, 2022. Her stated reason for departure is a desire to focus on board service for companies developing innovative medicines, suggesting a strategic shift in her personal board commitments rather than any issue with Quest Diagnostics itself. In response to Dr. Torley's departure, the Board of Directors has approved a reduction in its size, decreasing the number of directors from 10 to 9, effective at the Annual Meeting. This change is a procedural adjustment in light of her decision and does not appear to signal any broader governance or strategic changes for Quest Diagnostics based on the information provided in this filing.
QUEST DIAGNOSTICS INC 8-K/A Report, Executive Changes (Mar 1, 2022)
This 8-K filing from Quest Diagnostics Inc. (DGX) details the 2022 compensation package for Mr. Davis, a key executive. The Compensation Committee approved a base salary of $800,000, a target annual bonus of 100% of base salary, and a target long-term incentive (LTI) award with a grant date fair value of approximately $4.88 million. The LTI award is structured as a mix of performance shares, stock options, and restricted stock units, with specific performance metrics tied to base business revenue growth, COVID-19 testing revenue, return on invested capital, and relative total shareholder return. Investors should note that the terms of Mr. Davis's compensation are generally aligned with those of other senior executives. The performance metrics for the LTI award are designed to incentivize growth and profitability over a three-year period, reflecting the company's strategic objectives. While no significant executive departures or new appointments are reported, this filing provides transparency into executive remuneration and the performance drivers the company is focused on.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Mar 1, 2022)
This 8-K filing from Quest Diagnostics Inc. (DGX) on March 1, 2022, details significant compensation arrangements for key executives. Notably, the Compensation Committee approved a substantial special equity grant for Carrie Eglinton Manner, Senior Vice President of Advanced Diagnostics. This grant, valued at $1,940,235, is designed to incentivize revenue growth in her areas of responsibility, excluding COVID-19 testing and recent acquisitions, and is structured as 50% performance shares and 50% restricted stock units with a three-year cliff vesting period. Additionally, an annual equity grant was approved for Mark Guinan, Executive Vice President and Chief Financial Officer, valued at $1,122,566. This grant includes accelerated vesting upon retirement under specific conditions, and its value is approximately half of his 2021 grant due to his planned retirement in 2022. These adjustments reflect a focus on management succession and aligning executive incentives with strategic growth objectives.
QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Feb 3, 2022)
Quest Diagnostics Inc. (DGX) has announced a significant leadership transition plan through this Form 8-K filing. The company has appointed James E. Davis, currently Executive Vice President of General Diagnostics, as the next Chief Executive Officer and President, effective November 1, 2022. Mr. Davis will also serve as Chief Executive Officer – Elect starting February 3, 2022, indicating a deliberate and structured succession process. This change marks the upcoming retirement of the long-serving CEO, Stephen H. Rusckowski, who will transition to the role of Executive Chairman through March 2023. Additionally, the company disclosed that its Executive Vice President and Chief Financial Officer, Mark J. Guinan, will retire in 2022, with a search underway for his successor. These announcements reflect proactive leadership planning aimed at ensuring continuity and strategic direction for Quest Diagnostics.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Feb 3, 2022)
Quest Diagnostics Incorporated (DGX) filed an 8-K on February 3, 2022, primarily to report its fourth quarter and full-year 2021 financial results and announce a dividend increase. The company reported its performance for the period ending December 31, 2021, with detailed financial results included in the referenced press release. Investors should review this press release for specific revenue, earnings, and operational metrics.
QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jan 12, 2022)
Quest Diagnostics Inc. (DGX) filed an 8-K on January 12, 2022, to announce preliminary financial results for the fourth quarter and full year ended December 31, 2021, along with an initial outlook for 2022. This filing serves as an early indicator for investors regarding the company's recent performance and future expectations, signaling significant updates outside of the standard quarterly reporting cycle. Investors should pay close attention to the details within the press release attached as Exhibit 99.1 for a comprehensive understanding of these preliminary figures and forward-looking statements.